ECSP21051833A - Combinación de dextrometorfano y bupropión para el tratamiento de depresión - Google Patents
Combinación de dextrometorfano y bupropión para el tratamiento de depresiónInfo
- Publication number
- ECSP21051833A ECSP21051833A ECSENADI202151833A ECDI202151833A ECSP21051833A EC SP21051833 A ECSP21051833 A EC SP21051833A EC SENADI202151833 A ECSENADI202151833 A EC SENADI202151833A EC DI202151833 A ECDI202151833 A EC DI202151833A EC SP21051833 A ECSP21051833 A EC SP21051833A
- Authority
- EC
- Ecuador
- Prior art keywords
- bupropion
- dextrometorphan
- depression
- treatment
- combination
- Prior art date
Links
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001058 bupropion Drugs 0.000 title abstract 2
- 208000020401 Depressive disease Diseases 0.000 title 1
- MKXZASYAUGDDCJ-CGTJXYLNSA-N levomethorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(C)[C@@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-CGTJXYLNSA-N 0.000 title 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 abstract 2
- 229960001985 dextromethorphan Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se divulgan las formas de dosificación, sistemas de suministro de fármacos y métodos relacionados con la liberación sostenida de dextrometorfano o efectos terapéuticos mejorados. Típicamente, bupropión o un compuesto relacionado se administra por vía oral a un ser humano a ser tratado con o que es tratado con dextrometorfano.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789431P | 2019-01-07 | 2019-01-07 | |
| US201962789446P | 2019-01-07 | 2019-01-07 | |
| US201962789488P | 2019-01-07 | 2019-01-07 | |
| US201962789451P | 2019-01-07 | 2019-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21051833A true ECSP21051833A (es) | 2021-11-18 |
Family
ID=71521902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202151833A ECSP21051833A (es) | 2019-01-07 | 2021-07-13 | Combinación de dextrometorfano y bupropión para el tratamiento de depresión |
Country Status (28)
| Country | Link |
|---|---|
| EP (2) | EP3908270B1 (es) |
| JP (1) | JP2022516361A (es) |
| KR (2) | KR20240169131A (es) |
| CN (4) | CN114712357A (es) |
| AU (3) | AU2020207261B2 (es) |
| BR (1) | BR112020025902A2 (es) |
| CA (2) | CA3223187A1 (es) |
| CL (1) | CL2021001810A1 (es) |
| CO (1) | CO2021008988A2 (es) |
| CR (1) | CR20210368A (es) |
| DK (1) | DK3908270T3 (es) |
| EC (1) | ECSP21051833A (es) |
| ES (1) | ES3051232T3 (es) |
| FI (1) | FI3908270T3 (es) |
| HR (1) | HRP20251402T1 (es) |
| IL (1) | IL284663A (es) |
| LT (1) | LT3908270T (es) |
| MX (1) | MX2021008247A (es) |
| MY (1) | MY201603A (es) |
| NZ (1) | NZ777261A (es) |
| PE (1) | PE20212249A1 (es) |
| PL (1) | PL3908270T3 (es) |
| PT (1) | PT3908270T (es) |
| RS (1) | RS67453B1 (es) |
| SG (1) | SG11202106392RA (es) |
| SI (1) | SI3908270T1 (es) |
| SM (1) | SMT202600055T1 (es) |
| WO (1) | WO2020146412A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12569479B2 (en) | 2016-05-25 | 2026-03-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| SG11202106392RA (en) * | 2019-01-07 | 2021-07-29 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| KR20230113787A (ko) | 2020-12-01 | 2023-08-01 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판 |
| CN117693336A (zh) * | 2021-07-21 | 2024-03-12 | 安泰赛普生物风投二代有限责任公司 | 抑郁症的治疗 |
| KR20240046749A (ko) * | 2021-08-09 | 2024-04-09 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 우울 증상의 관해를 유지하는 방법 |
| CN119212709A (zh) * | 2022-05-17 | 2024-12-27 | 安泰赛普生物风投二代有限责任公司 | 抑郁的治疗 |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US12194036B2 (en) | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| WO2025117954A1 (en) * | 2023-12-01 | 2025-06-05 | Axsome Therapeutics, Inc. | Compounds and combinations thereof for treating depression in patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009525343A (ja) * | 2006-02-03 | 2009-07-09 | アバニール・ファーマシューティカルズ | 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物 |
| CA2886573C (en) * | 2012-10-11 | 2019-04-02 | Stephen Lim Chin Beng | Solid dosage form |
| JP6406713B2 (ja) * | 2013-01-30 | 2018-10-17 | ファーモレックス セラピューティクス， インコーポレイテッド | 低用量薬剤によるうつ病および他の疾患の処置 |
| US9402843B2 (en) * | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US10512643B2 (en) * | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| KR102603013B1 (ko) * | 2013-11-05 | 2023-11-15 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법 |
| EP4166141A1 (en) * | 2014-09-14 | 2023-04-19 | Avanir Pharmaceuticals, Inc. | Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation and aggression in alzheimer's dementia |
| KR101931896B1 (ko) * | 2014-11-21 | 2018-12-21 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법 |
| SG11202106392RA (en) * | 2019-01-07 | 2021-07-29 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
-
2020
- 2020-01-07 SG SG11202106392RA patent/SG11202106392RA/en unknown
- 2020-01-07 JP JP2021539451A patent/JP2022516361A/ja active Pending
- 2020-01-07 NZ NZ777261A patent/NZ777261A/en unknown
- 2020-01-07 PL PL20737928.0T patent/PL3908270T3/pl unknown
- 2020-01-07 FI FIEP20737928.0T patent/FI3908270T3/fi active
- 2020-01-07 CR CR20210368A patent/CR20210368A/es unknown
- 2020-01-07 ES ES20737928T patent/ES3051232T3/es active Active
- 2020-01-07 CN CN202210286767.XA patent/CN114712357A/zh active Pending
- 2020-01-07 BR BR112020025902-0A patent/BR112020025902A2/pt not_active Application Discontinuation
- 2020-01-07 CA CA3223187A patent/CA3223187A1/en active Pending
- 2020-01-07 EP EP20737928.0A patent/EP3908270B1/en active Active
- 2020-01-07 KR KR1020247038482A patent/KR20240169131A/ko active Pending
- 2020-01-07 HR HRP20251402TT patent/HRP20251402T1/hr unknown
- 2020-01-07 CN CN202210286580.XA patent/CN114712356A/zh active Pending
- 2020-01-07 RS RS20251154A patent/RS67453B1/sr unknown
- 2020-01-07 DK DK20737928.0T patent/DK3908270T3/da active
- 2020-01-07 CN CN202210286769.9A patent/CN114712358A/zh active Pending
- 2020-01-07 MX MX2021008247A patent/MX2021008247A/es unknown
- 2020-01-07 SI SI202030682T patent/SI3908270T1/sl unknown
- 2020-01-07 EP EP25191016.2A patent/EP4631571A3/en active Pending
- 2020-01-07 WO PCT/US2020/012612 patent/WO2020146412A1/en not_active Ceased
- 2020-01-07 PT PT207379280T patent/PT3908270T/pt unknown
- 2020-01-07 SM SM20260055T patent/SMT202600055T1/it unknown
- 2020-01-07 PE PE2021001138A patent/PE20212249A1/es unknown
- 2020-01-07 MY MYPI2021003336A patent/MY201603A/en unknown
- 2020-01-07 AU AU2020207261A patent/AU2020207261B2/en active Active
- 2020-01-07 LT LTEPPCT/US2020/012612T patent/LT3908270T/lt unknown
- 2020-01-07 CA CA3126062A patent/CA3126062C/en active Active
- 2020-01-07 CN CN202080004041.1A patent/CN112437659B/zh active Active
- 2020-01-07 KR KR1020217023974A patent/KR20210110654A/ko not_active Ceased
-
2021
- 2021-07-06 IL IL284663A patent/IL284663A/en unknown
- 2021-07-07 CL CL2021001810A patent/CL2021001810A1/es unknown
- 2021-07-07 CO CONC2021/0008988A patent/CO2021008988A2/es unknown
- 2021-07-13 EC ECSENADI202151833A patent/ECSP21051833A/es unknown
-
2023
- 2023-07-06 AU AU2023204348A patent/AU2023204348B2/en active Active
-
2025
- 2025-05-23 AU AU2025203831A patent/AU2025203831A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001810A1 (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| MX2020008017A (es) | Formulaciones de vidrio y usos de las mismas. | |
| EA201890507A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| AR057946A1 (es) | Formulacion de zonisamida de liberacion sostenidda | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| ECSP22036502A (es) | Inhibidores del factor d del complemento para administraci?n oral | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| UY37413A (es) | Formulaciones de liberación inmediata de oprozomib | |
| PE20221314A1 (es) | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro | |
| PE20210370A1 (es) | Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion | |
| MX2022000426A (es) | Telmisartan para el tratamiento de la hipertension en perros. | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico | |
| PA8624501A1 (es) | Piperazinas derivadas de úrea para el tratamiento de la endometrosis | |
| CL2024000781A1 (es) | Formas farmacéuticas multipartículas que comprenden deutetrabenazina | |
| BR112018017167A2 (pt) | titulação de cebranopadol | |
| CO2021014967A2 (es) | Composiciones farmacéuticas de combinación a dosis fijas de liberación inmediata, métodos y usos de las mismas | |
| AR120453A1 (es) | Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer | |
| MX2016006375A (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
| CL2019002936A1 (es) | Uso de ácido 1-(aminometil) ciclohexanoacético para preparar un medicamento útil para el tratamiento y prevención de la enfermedad de alzheimer | |
| EA202190247A1 (ru) | ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |